Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Semi-annual Report for 2026

Aug 1, 2026 · Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

Semi-annual Report for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Abnormal Fluctuations in Stock TradingJul 4
Announcement on Resolutions of the 2025 Annual General MeetingJun 27
Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia AreataJun 16
Announcement on Using Partial Temporarily Idle Raised Funds for Cash ManagementJun 13

All Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases